ESMO 2022 – Keytruda secures a renal cancer monopoly

Merck & Co should be able to make its recently won claim to have the first anti-PD-(L)1 drug approved for adjuvant treatment of kidney cancer for some time to come. Judging by two late-breaking abstracts just revealed for the upcoming Esmo conference, its two rivals Bristol Myers Squibb and Roche slipped up here by similarly wide margins.